Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Cogent Biosciences Inc (NASDAQ: COGT) closed at $37.12 down -2.11% from its previous closing price of $37.92. In other words, the price has decreased by -$2.11 from its previous closing price. On the day, 2.15 million shares were traded. COGT stock price reached its highest trading level at $38.63 during the session, while it also had its lowest trading level at $36.54.
Ratios:
For a deeper understanding of Cogent Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.38 and its Current Ratio is at 6.38. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.19.
On November 10, 2025, Stifel Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $40.
On October 16, 2025, Stifel started tracking the stock assigning a Hold rating and target price of $16.Stifel initiated its Hold rating on October 16, 2025, with a $16 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 26 ’25 when Kearns Evan sold 65,000 shares for $38.70 per share. The transaction valued at 2,515,500 led to the insider holds 109,398 shares of the business.
Green John L. sold 77,000 shares of COGT for $2,978,360 on Dec 26 ’25. The Chief Financial Officer now owns 131,834 shares after completing the transaction at $38.68 per share. On Dec 26 ’25, another insider, Sachs Jessica, who serves as the Chief Medical Officer of the company, sold 82,642 shares for $38.70 each. As a result, the insider received 3,198,245 and left with 133,938 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COGT now has a Market Capitalization of 5698126336 and an Enterprise Value of 5065358336.
Stock Price History:
The Beta on a monthly basis for COGT is 0.49, which has changed by 3.8615384 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, COGT has reached a high of $43.73, while it has fallen to a 52-week low of $3.72. The 50-Day Moving Average of the stock is 19.08%, while the 200-Day Moving Average is calculated to be 152.36%.
Shares Statistics:
For the past three months, COGT has traded an average of 3.21M shares per day and 2340700 over the past ten days. A total of 139.83M shares are outstanding, with a floating share count of 123.61M. Insiders hold about 18.71% of the company’s shares, while institutions hold 87.34% stake in the company. Shares short for COGT as of 1765756800 were 14717421 with a Short Ratio of 4.58, compared to 1763078400 on 15477473. Therefore, it implies a Short% of Shares Outstanding of 14717421 and a Short% of Float of 10.75.
Earnings Estimates
A comprehensive evaluation of Cogent Biosciences Inc (COGT) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.38 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.96 and -$2.47 for the fiscal current year, implying an average EPS of -$2.25. EPS for the following year is -$1.73, with 11.0 analysts recommending between -$0.88 and -$2.25.
